1. Home
  2. FGEN vs INKT Comparison

FGEN vs INKT Comparison

Compare FGEN & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGEN
  • INKT
  • Stock Information
  • Founded
  • FGEN 1993
  • INKT 2017
  • Country
  • FGEN United States
  • INKT United States
  • Employees
  • FGEN N/A
  • INKT N/A
  • Industry
  • FGEN Biotechnology: Pharmaceutical Preparations
  • INKT Medicinal Chemicals and Botanical Products
  • Sector
  • FGEN Health Care
  • INKT Health Care
  • Exchange
  • FGEN Nasdaq
  • INKT Nasdaq
  • Market Cap
  • FGEN 34.5M
  • INKT 43.0M
  • IPO Year
  • FGEN 2014
  • INKT 2021
  • Fundamental
  • Price
  • FGEN $0.50
  • INKT $11.00
  • Analyst Decision
  • FGEN
  • INKT Strong Buy
  • Analyst Count
  • FGEN 0
  • INKT 2
  • Target Price
  • FGEN N/A
  • INKT $6.50
  • AVG Volume (30 Days)
  • FGEN 885.8K
  • INKT 71.7K
  • Earning Date
  • FGEN 02-24-2025
  • INKT 03-20-2025
  • Dividend Yield
  • FGEN N/A
  • INKT N/A
  • EPS Growth
  • FGEN N/A
  • INKT N/A
  • EPS
  • FGEN N/A
  • INKT N/A
  • Revenue
  • FGEN $180,015,000.00
  • INKT N/A
  • Revenue This Year
  • FGEN $21.91
  • INKT N/A
  • Revenue Next Year
  • FGEN N/A
  • INKT N/A
  • P/E Ratio
  • FGEN N/A
  • INKT N/A
  • Revenue Growth
  • FGEN 16.15
  • INKT N/A
  • 52 Week Low
  • FGEN $0.18
  • INKT $4.56
  • 52 Week High
  • FGEN $2.93
  • INKT $19.00
  • Technical
  • Relative Strength Index (RSI)
  • FGEN 49.50
  • INKT 59.75
  • Support Level
  • FGEN $0.46
  • INKT $7.32
  • Resistance Level
  • FGEN $0.51
  • INKT $13.79
  • Average True Range (ATR)
  • FGEN 0.05
  • INKT 2.07
  • MACD
  • FGEN -0.01
  • INKT 0.28
  • Stochastic Oscillator
  • FGEN 31.25
  • INKT 71.94

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

Share on Social Networks: